1. Clinical Overview

Molecule: Stabilized synthetic GHRH analog, 44 amino acids, with trans-3-hexenoyl group for increased stability, half-life, and pituitary potency

Classification: Enhanced GHRH analog • Visceral-fat reduction • Anti-aging/metabolic • Cognitive support

FDA Approval: HIV-associated lipodystrophy (visceral adiposity). Egrifta®.

Stronger, longer-acting, and more targeted than Sermorelin (GRF 1–29). Off-label: visceral fat reduction in non-HIV, anti-aging, GH optimization, body recomposition, cognitive/metabolic support.

2. Mechanisms of Action

2.1 Enhanced GHRH Receptor Activation

Binds GHRH receptor on somatotrophs: ↑ GH pulse amplitude/frequency, ↑ IGF-1. Higher and more sustained GH secretion vs Sermorelin.

2.2 Preferential VAT Reduction

10–20% visceral fat reduction. Preferential organ-surrounding fat loss, reduced VAT biomarkers. GH-driven lipolysis, IGF-1 adipocyte remodeling, reduced hepatic fat.

2.3 Glucose & Lipid Metabolism

Decreased fasting triglycerides, improved lipid profile, reduced cytokines, mild glycemic improvement.

2.4 Cognition & Neuroprotection

Memory consolidation, hippocampal neurogenesis, reduced brain inflammation, cognitive performance in aging.

2.5 Anti-Aging & Repair

GH/IGF-1: collagen synthesis, tissue healing, training recovery, bone density, skin rejuvenation.

3. Clinical Applications

3.1 Visceral Fat (Primary)

Abdominal/organ-surrounding/liver fat, cardiometabolic risk. Middle-aged men, postmenopausal women, metabolic syndrome.

3.2 Body Recomposition

Lean mass retention, fat loss with muscle preservation, post-liposuction contour.

3.3 Anti-Aging & Longevity

Better sleep, recovery, energy, skin elasticity.

3.4 Cognitive Enhancement

Short-term memory, recall, spatial cognition. Age-related decline, chronic stress, poor sleep.

3.5 GH Optimization Without HGH

Preserves pulsatile GH, no endogenous suppression, minimizes overdose risk, avoids supraphysiologic IGF-1.

4. Administration & Protocols

VAT Reduction (FDA model): 2 mg SC nightly
Anti-Aging / Longevity: 1 mg SC nightly
Body Recomposition: 1–2 mg SC nightly ± SLU-PP-332, AOD-9604
Cognitive / Neuroprotection: 0.5–1 mg nightly

Cycling

VAT: 3–6 months continuous. Recomposition: 8–12 week cycles. Anti-aging: ongoing low-dose nightly.

Notes

Take at night. Avoid food 1–2 hrs pre/post (carbs/fats). Best during calorie deficit.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ CJC-1295 (No DAC): Synergistic GH-axis — strong GHRH + extended pituitary stimulation
+ Ipamorelin: Dual secretagogue — GHRH + GHRP = maximal physiologic GH
+ SLU-PP-332: Thermogenesis + GH — VAT, mitochondrial, metabolic flexibility
+ AOD-9604: Targets stubborn abdominal fat
+ BPC-157 + TB-500: Orthopedic injury/recovery
+ MOTS-c / SS-31 / NAD+: Longevity, performance, fatigue, mitochondrial optimization

6. Clinical Decision Trees

Tree 1 — Is Tesamorelin Indicated?

Excess visceral fat? → YES

Metabolic syndrome? → YES

Cognitive decline + visceral adiposity? → YES

HGH-like benefits without HGH? → YES

Active cancer? → NO

Uncontrolled diabetes? → CAUTION

Tree 2 — Dose Strategy

VAT reduction → 2 mg SC nightly

Anti-aging → 1 mg SC nightly

Cognitive → 0.5–1 mg nightly

Recomposition → 1–2 mg nightly

7. Integrated Archetypes

A — Visceral-Fat Targeting

Tesamorelin 2 mg nightly + SLU-PP-332 + AOD-9604 + low-carb nutrition
Outcome: Substantial abdominal fat reduction.

B — Longevity / Anti-Aging

Tesamorelin 1 mg nightly + NAD+ weekly + DSIP sleep + GHK-Cu skin
Outcome: Full-spectrum rejuvenation.

C — Body Recomposition

Tesamorelin 1–2 mg nightly + IGF-1 LR3 post-workout + MGF satellite-cell activation
Outcome: Lean muscle + fat loss.

D — Cognitive Enhancement

Tesamorelin 0.5–1 mg nightly + Semax/Selank + Pinealon + SS-31
Outcome: Sharper memory + neuroprotection.

8. Expected Timeline

Week 1–2: Improved sleep & recovery
Week 3–4: Reduced waist circumference
Month 2–3: 8–12% visceral fat reduction
Month 3–6: 10–20% VAT reduction, improved composition
Long-term: Stable cognitive & metabolic benefits

9. Contraindications

Absolute

Active cancer
Pregnancy / Breastfeeding

Relative

Uncontrolled diabetes
Severe liver disease
Active gallbladder disease
Pituitary tumors
Severe sleep apnea

10. Adverse Effects

Common: Injection-site redness, mild water retention, muscle tightness, fatigue, headache. Less common: Hyperglycemia, carpal-tunnel symptoms, peripheral edema. Rare: Elevated IGF-1, insulin resistance (high doses).

11. Monitoring

IGF-1 baseline & q12 weeks
Fasting insulin/glucose
Lipid profile
A1C (metabolic risk)
Waist/hip ratio
Body composition
Liver function (NASH risk)

Legal Disclaimer

This document is provided solely for educational and informational purposes. Tesamorelin and other peptides referenced herein may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Tesamorelin

Foundational GHRH Biology

1. Thorner, M. O., et al. GHRH regulation of GH. NEJM, 309(12), 690–695 (1983).

2. Giustina, A., & Veldhuis, J. D. GH pulsatility. Endocr Rev, 19(6), 717–797 (1998).

3. Müller, E. E., et al. Neuroendocrine GH control. Physiol Rev, 79(2), 511–607 (1999).

Mechanism & PK

4. Falutz, J., et al. Tesamorelin PK/PD. J Clin Endocrinol Metab, 90(12), 6794–6801 (2005).

5. Teichman, S. L., et al. GHRH analog half-life/binding. Endocr Rev, 27(1), 75–97 (2006).

6. Walker, R. F., et al. Stable GHRH analog design. Endocrinology, 122(6), 2212–2219 (1988).

Pivotal HIV Lipodystrophy Trials

7. Falutz, J., et al. Pivotal Phase 3 VAT reduction. NEJM, 362(6), 518–528 (2010).

8. Stanley, T. L., et al. VAT, IMAT, metabolic risk. J Clin Endocrinol Metab, 99(2), 469–477 (2014).

9. Stanley, T. L., et al. Long-term VAT/cardiometabolic. Clin Infect Dis, 60(1), 151–159 (2015).

10. Falutz, J., et al. 52-week VAT durability. AIDS, 22(14), 1719–1727 (2008).

Body Composition & Metabolic

11. Stanley, T. L., et al. Body composition/cardiometabolic. Diabetes Care, 37(11), 3287–3294 (2014).

12. Lenhard, J. M., et al. Lipid oxidation/metabolic rate. Metabolism, 63(2), 215–220 (2014).

13. Sutinen, J., et al. GH pathway abdominal fat. J Clin Endocrinol Metab, 88(11), 5503–5509 (2003).

Hepatic & NAFLD/NASH

14. Stanley, T. L., et al. Liver fat/NASH markers. Lancet HIV, 6(6), e444–e451 (2019).

15. Mavrotas, G., et al. GHRH hepatic regulation. J Hepatol, 59(1), 171–178 (2013).

16. Lo, J., et al. Hepatic triglyceride/MRI-PDFF. Clin Infect Dis, 73(2), e393–e402 (2021).

Insulin & IGF-1

17. Makimura, H., et al. IGF-1/insulin sensitivity. J Clin Endocrinol Metab, 101(1), 117–125 (2016).

18. Veldhuis, J. D., et al. GH pulsatility metabolic function. Metabolism, 53(1), 74–82 (2004).

19. Stanley, T. L., et al. Insulin sensitivity in HIV. Am J Clin Nutr, 98(2), 391–399 (2013).

Cardiometabolic & Inflammatory

20. Haugaard, S. B., et al. Inflammation/adipokines. Horm Metab Res, 48(3), 179–185 (2016).

21. Lo, J., et al. CV risk markers in HIV. J Clin Endocrinol Metab, 94(7), 2343–2349 (2009).

22. Kuk, J. L., et al. GH inflammatory biomarkers. Endocr Rev, 34(1), 12–28 (2013).

Comparative GHRH Analogs

23. Teichman, S. L., et al. Sermorelin/CJC-1295/Tesamorelin. J Clin Endocrinol Metab, 91(3), 799–805 (2006).

24. Falutz, J., et al. GHRH metabolic differences. Metabolism, 63(8), 1043–1051 (2014).

Safety & Tolerability

25. Falutz, J., et al. Long-term safety. AIDS Res Hum Retrovir, 25(4), 421–427 (2009).

26. Stanley, T. L., et al. Adverse events vs placebo. Clin Infect Dis, 52(7), 952–963 (2011).

27. FDA CDER. Egrifta® approval/safety. FDA, 2010–2023.

Future Directions

28. Lo, J., et al. NAFLD/NASH beyond HIV. Hepatol Commun, 5(11), 1814–1824 (2021).

29. Stanley, T. L., et al. Metabolic syndrome/visceral obesity. Nat Rev Endocrinol, 17(12), 759–767 (2021).